Merck Reports P-III Trial (KEYNOTE-671) of Keytruda for Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
- The P-III trial (KEYNOTE-671) evaluating neoadjuvant Keytruda + CT vs PBO + CT in a ratio (1:1) in 786 patients with resectable stage II, IIIA, or IIIB (T3-4N2) NSCLC
- The trial met its 1EPs of EFS as a perioperative treatment regimen while the trial will continue to evaluate the other dual 1EPs of OS. In a prespecified interim analysis, neoadjuvant Keytruda + CT showed a clinical improvement in EFS, followed by resection & adjuvant single-agent Keytruda, improvements in the 2EPs of pCR & mPR with no new safety signals
- The US FDA has accepted a new sBLA of Keytruda in combination with Pt containing CT as neoadjuvant treatment, and then continued as monotx. as adjuvant treatment & the PDUFA date is expected on Oct 16, 2023
Ref: Merck | Image: Merck
Related Post:- Moderna and Merck Receive the US FDA’s Breakthrough Therapy Designation for mRNA-4157/V940 + Keytruda (pembrolizumab) to Treat High-Risk Melanoma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].